Albumin Use in Pleural Effusions Due to Cirrhosis

Introduction to Albumin Therapy

The American Association for the Study of Liver Diseases recommends albumin administration in cirrhotic patients with spontaneous bacterial empyema (SBE) when pleural fluid PMN count >250/mm³, particularly in those with renal dysfunction or severe hepatic decompensation 1, 2, 3

Albumin should be administered to cirrhotic patients with SBE and pleural fluid PMN count >250/mm³, especially if there is renal dysfunction or severe hepatic decompensation, as it improves survival by preventing progression of acute kidney injury (AKI) 1, 2, 3
The European Association for the Study of the Liver suggests that treatment should primarily target the underlying cause of hypoalbuminemia, such as cirrhosis, rather than the hypoalbuminemia itself 4

The American Association for the Study of Liver Diseases indicates that albumin has a specific, evidence-based role in cirrhotic patients with SBE when pleural fluid PMN count >250/mm³, particularly in those with renal dysfunction or severe hepatic decompensation 1, 2, 3

The recommended dosing regimen for albumin administration in cirrhotic patients with SBE is 1.5 g/kg IV on day 1 and 1.0 g/kg IV on day 3 1, 2, 3

Albumin functions beyond simple volume expansion in cirrhotic patients with infection, reducing systemic inflammation, preventing circulatory dysfunction, and preventing AKI progression, which is the main predictor of in-hospital mortality 1, 2, 3

The American Association for the Study of Liver Diseases advises against targeting serum albumin levels, as a 2024 trial showed that targeting serum albumin levels of 3 g/dL in hospitalized cirrhotic patients resulted in significantly higher rates of pulmonary edema and fluid overload without benefit 5
The European Association for the Study of the Liver recommends recognizing transudative vs. exudative effusions, as hypoalbuminemia typically causes transudative effusions (serum-effusion albumin gradient >1.2 g/dL) 4